Why I’d stash banking stocks and pharma stocks in my 2018 ISA

Here’s why the banking and pharmaceutical sectors could provide great long-term ISA investments.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The new tax year arrives in April, and with it comes a whole new tax-free allowance of £20,000. 

What that means is you’ll be able to invest up to £20,000 in your ISA in the 2018/19 tax year, and you won’t have to pay a penny in tax on any money you take out — regardless of how well your investments grow.

Now that’s a significant sum and not many people will have that much to spare to invest every year, but using up as much of the allowance as you can is very much to your advantage.

It’s good to utilize as much of your existing 2017/18 ISA as you can in the next few weeks. But what should you then consider for the new one?

Cash is king

You might be surprised to learn that I rate the banking sector highly, despite the crash that knocked our economy for six. But it’s arguable that we really did need that short-term shock in order to shake up the excesses of the banking business, and I reckon we’re looking at a far safer sector than we’ve seen for decades.

My favourite of the big banks is Lloyds Banking Group, which is back to paying healthy and growing dividends, with yields of better than 6% currently forecast. There’s even been a bit of share price growth over the past five years, of 34%, and the shares are still lowly valued on a P/E of under nine.

HSBC Holdings is offering better than 5% and there’s decent earnings growth on the cards. Even Barclays shareholders are seeing a return to dividends — the yield is expected to reach only around 3.7% by 2019, but it’s growing rapidly and should be very well covered by eanrings.

I’d consider the smaller “challenger” banks too, which are sticking to safe UK-centric retail banking. Virgin Money Holdings is looking good value to me, on P/E multiples of under eight and with dividends modest at around 2.5%, but growing ahead of inflation.

Growing demand

The pharmaceuticals sector has also long been a favourite of mine, as demand for health services from ageing Western populations, coupled with increasing wealth in developing nations, should keep the profits rolling in.

The UK’s top two, GlaxoSmithKline and AstraZeneca, are still getting over recent hits through the expiry of some key patents and the resulting stiffer competition from generic alternatives, but both have been investing heavily in their drug development pipelines. 

And again, we’re looking at long-term generators of cash. Even throughout the patent-led down spell, both the giants kept paying out dividends that were firmly ahead of the FTSE 100‘s long-term average. 

As a return to earnings growth is edging closer for AstraZeneca, analysts are forecasting dividend yields of 4.3%. They wouldn’t be well covered yet and there is a bit of risk there, but I see underlying long-term safety.

And at GlaxoSmithKline, which has already recovered to put in a couple of years of growth, the prognosis is for yields of better than 6%.

There are also plenty of newcomers to the pharma and biotech fields, which are researching potentially exciting areas, if you want to add a bit of excitement to your ISA. But if you went for one of the biggest and best from each sector, I think you’d be off to a great start.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft owns shares in Lloyds Banking Group. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca, Barclays, HSBC Holdings, and Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

Could Raspberry Pi shares hit £5 by 2030?

After a strong start out of the blocks this month, our writer asks whether Raspberry Pi shares could move further…

Read more »

Close-up of British bank notes
Investing Articles

Five 5%+ yielders I’d buy for an ISA today!

Our writer identifies a handful of FTSE 100 and FTSE 250 firms each yielding at least 5% he'd happily buy…

Read more »

Front view photo of a woman using digital tablet in London
Investing Articles

5 stocks with 5%+ yields I’d love to buy and hold in a Stocks and Shares ISA

Harvey Jones is keen to add these five FTSE 100 high-yielders to his Stocks and Shares ISA, ideally before they…

Read more »

A young Asian woman holding up her index finger
Investing Articles

I’d target £880 of passive income annually, spending £10K now on this FTSE 100 share

Our writer explains how he would add to his diversified portfolio happily by investing in this FTSE 100 passive income…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

3 reasons I think the Scottish Mortgage share price could keep rising

Christopher Ruane explains a trio of reasons he thinks the once-mighty Scottish Mortgage share price could be set to increase…

Read more »

Syringe and vial on blue background
Investing Articles

Is this forgotten FTSE share about to make investors rich all over again?

Not long ago, this FTSE share was all the rage before demand dropped off and things went south. Is it…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

I’d use these 5 Warren Buffett approaches to build wealth

Christopher Ruane outlines a handful of investing lessons from billionaire Warren Buffett that he thinks can help a small investor…

Read more »

US Stock

Nvidia stock: 3 things investors need to know as it surges towards $150

Nvidia is a stock that's had an extraordinary run in 2024. Edward Sheldon highlights some important things investors should know.

Read more »